Determination of the Risk of Tumor Progression in Patients with Early Stages of Adenocarcinoma and Squamous Cell Lung Carcinoma Based on Laboratory Parameters

IF 0.6 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry Pub Date : 2022-05-17 DOI:10.1134/S1990750822020081

A. D. Tahanovich, N. N. Kauhanka, V. I. Prohorova, D. I. Murashka, O. V. Gotko

{"title":"Determination of the Risk of Tumor Progression in Patients with Early Stages of Adenocarcinoma and Squamous Cell Lung Carcinoma Based on Laboratory Parameters","authors":"A. D. Tahanovich, N. N. Kauhanka, V. I. Prohorova, D. I. Murashka, O. V. Gotko","doi":"10.1134/S1990750822020081","DOIUrl":null,"url":null,"abstract":"<div><div><h3>\n <b>Abstract</b>—</h3><p>Non-small cell lung cancer (NSCLC) dominates in the morbidity of lung cancer. In stage I, only 60–70% patients overcome the 5-year survival barrier, and in stage II 5-year survival rate is declining to 35–40%. The reason for such a high mortality is relapse of the disease. The main histological forms of NSCLC are adenocarcinoma (AС) and squamous cell carcinoma (SCC). They differ in course, protocols and effectiveness of treatment. Comparative survival data for AC and SCC are controversial, and reliable biomarkers for determining the risk of tumor progression still have not been found. In order to determine the risk of disease progression we have investigated the possibility of using laboratory parameters characterizing the level of some blood proteins involved in carcinogenesis in patients with early stages of AС and SCC. We retrospectively analyzed the duration of relapse-free period after surgical treatment for one year in 1250 patients (816 with stages I and II AC, G1-3 and 434 with early stages of SCC, G1-3). In 81 AC patients and 36 SCC patients (stages I−II, G1-3) we determined the level of CYFRA 21-1 and SCC, TPA, chemokines CXCL5, CXCL8, pyruvate kinase M2, HIF-1α, hyaluronic acid and receptors CXCR1, CXCR2, CD44v6. Using the Kaplan−Meier graphical analysis, groups of low (stage I G1-2 + stage II G1) and high (stage I G3 + stage II G2-3) risk of tumor progression were identified. The one-year survival rate of AС patients was higher than in SCC patients. AС patients with high risk of tumor recurrence had higher levels of CYFRA 21-1, the mean intensity of fluorescence (MFI) of CXCR1 receptor in granulocytes, and the relative content of CXCR2 receptor in lymphocytes than patients with low risk. In the case of rapid disease progression in SCC patients, the relative content of CXCR2 receptor in lymphocytes, the proportion of monocytes supplied with CD44v6 receptor, and SCC level were higher than in patients with slow progression. Regression equations, including combinations of the above parameters (threshold value for AC—0.512, for SCC—0.409, sensitivity—91.9% and 90.0%, specificity—90.0% and 87.5%, respectively), allow to predict the probability of tumor recurrence.</p></div></div>","PeriodicalId":485,"journal":{"name":"Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry","volume":"16 2","pages":"154 - 163"},"PeriodicalIF":0.6000,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry","FirstCategoryId":"2","ListUrlMain":"https://link.springer.com/article/10.1134/S1990750822020081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract—

Non-small cell lung cancer (NSCLC) dominates in the morbidity of lung cancer. In stage I, only 60–70% patients overcome the 5-year survival barrier, and in stage II 5-year survival rate is declining to 35–40%. The reason for such a high mortality is relapse of the disease. The main histological forms of NSCLC are adenocarcinoma (AС) and squamous cell carcinoma (SCC). They differ in course, protocols and effectiveness of treatment. Comparative survival data for AC and SCC are controversial, and reliable biomarkers for determining the risk of tumor progression still have not been found. In order to determine the risk of disease progression we have investigated the possibility of using laboratory parameters characterizing the level of some blood proteins involved in carcinogenesis in patients with early stages of AС and SCC. We retrospectively analyzed the duration of relapse-free period after surgical treatment for one year in 1250 patients (816 with stages I and II AC, G1-3 and 434 with early stages of SCC, G1-3). In 81 AC patients and 36 SCC patients (stages I−II, G1-3) we determined the level of CYFRA 21-1 and SCC, TPA, chemokines CXCL5, CXCL8, pyruvate kinase M2, HIF-1α, hyaluronic acid and receptors CXCR1, CXCR2, CD44v6. Using the Kaplan−Meier graphical analysis, groups of low (stage I G1-2 + stage II G1) and high (stage I G3 + stage II G2-3) risk of tumor progression were identified. The one-year survival rate of AС patients was higher than in SCC patients. AС patients with high risk of tumor recurrence had higher levels of CYFRA 21-1, the mean intensity of fluorescence (MFI) of CXCR1 receptor in granulocytes, and the relative content of CXCR2 receptor in lymphocytes than patients with low risk. In the case of rapid disease progression in SCC patients, the relative content of CXCR2 receptor in lymphocytes, the proportion of monocytes supplied with CD44v6 receptor, and SCC level were higher than in patients with slow progression. Regression equations, including combinations of the above parameters (threshold value for AC—0.512, for SCC—0.409, sensitivity—91.9% and 90.0%, specificity—90.0% and 87.5%, respectively), allow to predict the probability of tumor recurrence.

Abstract Image

查看原文本刊更多论文

基于实验室参数测定早期腺癌和鳞状细胞肺癌患者肿瘤进展风险

非小细胞肺癌(NSCLC)在肺癌发病率中占主导地位。在I期，只有60-70%的患者克服了5年生存障碍，而在II期，5年生存率下降到35-40%。死亡率如此之高的原因是疾病的复发。非小细胞肺癌的主要组织学形式是腺癌(AС)和鳞状细胞癌(SCC)。它们在疗程、方案和治疗效果上有所不同。AC和SCC的比较生存数据存在争议，确定肿瘤进展风险的可靠生物标志物仍未发现。为了确定疾病进展的风险，我们研究了在早期AС和SCC患者中使用实验室参数表征一些参与癌变的血液蛋白水平的可能性。我们回顾性分析了1250例患者手术治疗后一年的无复发时间(816例为ⅰ期和ⅱ期AC, G1-3, 434例为早期SCC, G1-3)。在81例AC患者和36例SCC患者(I - II期，G1-3期)中，我们检测了CYFRA 21-1和SCC、TPA、趋化因子CXCL5、CXCL8、丙酮酸激酶M2、HIF-1α、透明质酸和受体CXCR1、CXCR2、CD44v6的水平。通过Kaplan - Meier图形分析，将肿瘤进展风险分为低(I期G1-2 + II期G1)和高(I期G3 + II期G2-3)两组。AС患者的1年生存率高于SCC患者。AС肿瘤复发高危患者的CYFRA 21-1水平、粒细胞中CXCR1受体的平均荧光强度(MFI)、淋巴细胞中CXCR2受体的相对含量均高于低危患者。在SCC快速进展患者中，淋巴细胞中CXCR2受体的相对含量、CD44v6受体供血的单核细胞比例以及SCC水平均高于进展缓慢患者。回归方程，包括上述参数的组合(AC-0.512的阈值，SCC-0.409的阈值，敏感性分别为91.9%和90.0%，特异性分别为90.0%和87.5%)，可以预测肿瘤复发的概率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry BIOCHEMISTRY & MOLECULAR BIOLOGY-

CiteScore

1.10

自引率

0.00%

发文量

期刊介绍： Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry covers all major aspects of biomedical chemistry and related areas, including proteomics and molecular biology of (patho)physiological processes, biochemistry, neurochemistry, immunochemistry and clinical chemistry, bioinformatics, gene therapy, drug design and delivery, biochemical pharmacology, introduction and advertisement of new (biochemical) methods into experimental and clinical medicine. The journal also publishes review articles. All issues of the journal usually contain solicited reviews.